Jardiance (Empagliflozin)
Launch:
Jardiance was launched by Boehringer Ingelheim and Eli Lilly in 2014.
Manufacturer:
Boehringer Ingelheim and Eli Lilly
Global Sales in 2023:
Jardiance generated approximately $11 billion in global sales in 2023, reflecting its growing use in both diabetes and heart failure treatments.
Why It’s the Best:
Jardiance is an SGLT2 inhibitor that helps manage type 2 diabetes by preventing the kidneys from reabsorbing glucose, which is then excreted in the urine.
It has also shown significant cardiovascular benefits, reducing the risk of heart failure and cardiovascular death in patients with diabetes. Its dual action on blood sugar levels and cardiovascular health has made it a standout treatment in the diabetes market.